Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVIGATE-AD: LY3202626 in Mild Alzheimer's Disease Dementia
jRCT2080223321Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LY3202626 in Alzheimer's disease (AD) (3 arms), sponsored by Eli Lilly and Company. Started Sep 2016; status: recruiting.
02
Drugs
LY3202626
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080223321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223321.